Scholarlink

Purpose <p>Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction (DGBI) characterized by recurrent abdominal pain and altered bowel habits. Treatment typically focuses on symptom management without addressing underlying causes. This systematic review and meta-analysis aimed to explore the association between inflammatory markers and gut microbiome changes in individuals with IBS.</p> Methods <p>A systematic search of PubMed, Scopus, EMBASE, and CINAHL databases was conducted in June 2024, identifying 41 studies that compared inflammatory markers and gut microbial composition in patients with IBS versus healthy controls. Meta-analysis was performed using a random-effects model, reporting standard mean differences (SMD) for inflammatory markers and mean differences (MD) for microbiome data, with 95% confidence intervals (CI).</p> Results <p>The results showed significantly elevated pro-inflammatory markers in individuals with IBS, including Interleukin (IL)-6 (SMD =  − 2.64), Tumor Necrosis Factor (TNF)-α (SMD =  − 1.97), platelet-to-lymphocyte ratio (PLR, SMD =  − 0.98), and fecal calprotectin (FC, SMD =  − 0.42), while IL-10 was lower (SMD = 2.00). Microbiome analysis revealed increased Bacteroidetes (MD =  − 15.92) and decreased Firmicutes (MD = 16.85) in people with IBS.</p> Conclusion <p>These findings suggest that inflammation and gut microbial imbalance contribute to IBS, warranting further studies on their interplay and impact on the typical symptoms seen in IBS.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

The Interplay Between Immunological Status and Gut Microbial Dysbiosis in the Development of the Symptoms of Irritable Bowel Syndrome: A Systematic Review with Meta-Analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年9月3日

查看全文
  • Tasnia Ahmed,
  • Daniel A. Lemberg,
  • Andrew S. Day,
  • Steven T. Leach

摘要

Purpose

Irritable bowel syndrome (IBS) is a chronic disorder of gut–brain interaction (DGBI) characterized by recurrent abdominal pain and altered bowel habits. Treatment typically focuses on symptom management without addressing underlying causes. This systematic review and meta-analysis aimed to explore the association between inflammatory markers and gut microbiome changes in individuals with IBS.

Methods

A systematic search of PubMed, Scopus, EMBASE, and CINAHL databases was conducted in June 2024, identifying 41 studies that compared inflammatory markers and gut microbial composition in patients with IBS versus healthy controls. Meta-analysis was performed using a random-effects model, reporting standard mean differences (SMD) for inflammatory markers and mean differences (MD) for microbiome data, with 95% confidence intervals (CI).

Results

The results showed significantly elevated pro-inflammatory markers in individuals with IBS, including Interleukin (IL)-6 (SMD =  − 2.64), Tumor Necrosis Factor (TNF)-α (SMD =  − 1.97), platelet-to-lymphocyte ratio (PLR, SMD =  − 0.98), and fecal calprotectin (FC, SMD =  − 0.42), while IL-10 was lower (SMD = 2.00). Microbiome analysis revealed increased Bacteroidetes (MD =  − 15.92) and decreased Firmicutes (MD = 16.85) in people with IBS.

Conclusion

These findings suggest that inflammation and gut microbial imbalance contribute to IBS, warranting further studies on their interplay and impact on the typical symptoms seen in IBS.